程序性死亡蛋白-1 (programmed death 1, PD-1)是在免疫细胞上表达的免疫抑制分子,通过参与程序性细胞凋亡过程,对活化的T淋巴细胞进行负性调控,它与程序性死亡蛋白配体1 (programmed death ligand 1, PD-L1)组成的信号通路在自身免疫调节、肿瘤免疫及慢性病毒感染中均起着重要的作用,是自身免疫性疾病和肿瘤的潜在药物治疗靶点。同时,T细胞持续性表达PD-1可使免疫耗竭,导致人体免疫功能下降,T细胞耗竭发生在许多肿瘤及慢性病毒感染中。本文综述了T细胞中PD-1表达水平在肺部感染性疾病治疗过程中的变化,并对未来肺部感染性疾病的临床评估和治疗提出展望。
Programmed death 1 (PD-1) is an immunosuppressive molecule expressed on immune cells, which negatively regulates activated T lymphocytes by participating in the process of programmed apop-tosis, and its signaling pathway with programmed death ligand 1 (PD-L1) plays an important role in autoimmune regulation, tumor immunity and chronic viral infection, and is a potential drug target for autoimmune diseases and tumors. It is a potential therapeutic target for autoimmune diseases and tumors. At the same time, persistent expression of PD-1 in T cells can lead to immune deple-tion, resulting in a decline in human immune function, and T cell depletion occurs in many tumors and chronic viral infections. This article reviews the changes in PD-1 expression levels in T cells during the treatment of pulmonary infectious diseases and provides an outlook for the future clini-cal evaluation and treatment of pulmonary infectious diseases.
PD-1,机体免疫,肺炎,肺结核, Programmed Death 1 Organismal Immunity Pneumonia Tuberculosis摘要
程序性死亡蛋白-1 (programmed death 1, PD-1)是在免疫细胞上表达的免疫抑制分子,通过参与程序性细胞凋亡过程,对活化的T淋巴细胞进行负性调控,它与程序性死亡蛋白配体1 (programmed death ligand 1, PD-L1)组成的信号通路在自身免疫调节、肿瘤免疫及慢性病毒感染中均起着重要的作用,是自身免疫性疾病和肿瘤的潜在药物治疗靶点。同时,T细胞持续性表达PD-1可使免疫耗竭,导致人体免疫功能下降,T细胞耗竭发生在许多肿瘤及慢性病毒感染中。本文综述了T细胞中PD-1表达水平在肺部感染性疾病治疗过程中的变化,并对未来肺部感染性疾病的临床评估和治疗提出展望。
关键词
PD-1,机体免疫,肺炎,肺结核
Advances in PD-1 Expression Levels and Organismal Immunity in Pulmonary Infectious Diseases
Longzhi Zhang1, Manman Cheng2, Xianwei Wang2*
1School of Clinical Medicine, Jining Medical University, Jining Shandong
2Affiliated Hospital of Jining Medical University, Jining Shandong
Programmed death 1 (PD-1) is an immunosuppressive molecule expressed on immune cells, which negatively regulates activated T lymphocytes by participating in the process of programmed apoptosis, and its signaling pathway with programmed death ligand 1 (PD-L1) plays an important role in autoimmune regulation, tumor immunity and chronic viral infection, and is a potential drug target for autoimmune diseases and tumors. It is a potential therapeutic target for autoimmune diseases and tumors. At the same time, persistent expression of PD-1 in T cells can lead to immune depletion, resulting in a decline in human immune function, and T cell depletion occurs in many tumors and chronic viral infections. This article reviews the changes in PD-1 expression levels in T cells during the treatment of pulmonary infectious diseases and provides an outlook for the future clinical evaluation and treatment of pulmonary infectious diseases.
Keywords:Programmed Death 1, Organismal Immunity, Pneumonia, Tuberculosis
张龙志,程曼曼,王娴玮. PD-1表达水平与机体免疫在肺部感染性疾病中的研究进展Advances in PD-1 Expression Levels and Organismal Immunity in Pulmonary Infectious Diseases[J]. 临床医学进展, 2023, 13(01): 218-225. https://doi.org/10.12677/ACM.2023.131034
参考文献ReferencesQuezada, S.A. and Peggs, K.S. (2013) Exploiting CTLA-4, PD-1 and PD-L1 to Reactivate the Host Immune Response against Cancer. British Journal of Cancer, 108, 1560-1565. <br>https://doi.org/10.1038/bjc.2013.117Schütz, F., Stefanovic, S., Mayer, L., et al. (2017) PD-1/PD-L1 Pathway in Breast Cancer. Oncology Research and Treatment, 40, 294-297. <br>https://doi.org/10.1159/000464353Wu, X., Gu, Z., Chen, Y., et al. (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 17, 661-674. <br>https://doi.org/10.1016/j.csbj.2019.03.006Juneja, V.R., Mcguire, K.A., Manguso, R.T., et al. (2017) PD-L1 on Tumor Cells Is Sufficient for Immune Evasion in Immunogenic Tumors and Inhibits CD8 T Cell Cytotoxicity. The Journal of Experimental Medicine, 214, 895-904.
<br>https://doi.org/10.1084/jem.20160801Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., et al. (2015) Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway. Trends in Molecular Medicine, 21, 24-33. <br>https://doi.org/10.1016/j.molmed.2014.10.009Kwiecien, I., Skirecki, T., Polubiec-Kownacka, M., et al. (2019) Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response. Cancers (Basel), 11, 567. <br>https://doi.org/10.3390/cancers11040567Sharpe, A.H., Wherry, E.J., Ahmed, R., et al. (2007) The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nature Immunology, 8, 239-245. <br>https://doi.org/10.1038/ni1443Keir, M.E., Butte, M.J., Freeman, G.J., et al. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. <br>https://doi.org/10.1146/annurev.immunol.26.021607.090331Jurado, J.O., Alvarez, I.B., Pasquinelli, V., et al. (2008) Programmed Death (PD)-1: PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis. Journal of Immunology (Baltimore, Md: 1950), 181, 116-125. <br>https://doi.org/10.4049/jimmunol.181.1.116Alvarez, I.B., Pasquinelli, V., Jurado, J.O., et al. (2010) Role Played by the Programmed Death-1-Programmed Death Ligand Pathway during Innate Immunity against Mycobacterium tuberculosis. The Journal of Infectious Diseases, 202, 524-532. <br>https://doi.org/10.1086/654932Peng, W., Liu, C., Xu, C., et al. (2012) PD-1 Blockade Enhances T-Cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines. Cancer Research, 72, 5209-5218. <br>https://doi.org/10.1158/0008-5472.CAN-12-1187He, J., Hu, Y., Hu, M., et al. (2015) Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Scientific Reports, 5, Article No. 13110.
<br>https://doi.org/10.1038/srep13110Zinselmeyer, B.H., Heydari, S., Sacristán, C., et al. (2013) PD-1 Promotes Immune Exhaustion by Inducing Antiviral T Cell Motility Paralysis. The Journal of Experimental Medicine, 210, 757-774. <br>https://doi.org/10.1084/jem.20121416Yao, H., Wang, H., Li, C., et al. (2018) Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Frontiers in Immunology, 9, Article No. 1774. <br>https://doi.org/10.3389/fimmu.2018.01774Ghoneum, A., Afify, H., Salih, Z., et al. (2018) Role of Tumor Microenvironment in the Pathobiology of Ovarian Cancer: Insights and Therapeutic Opportunities. Cancer Medicine, 7, 5047-5056. <br>https://doi.org/10.1002/cam4.1741(2020) Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet (London, England), 396, 1204-1222.Torres, A., Cilloniz, C., Niederman, M.S., et al. (2021) Pneumonia. Nature Reviews Disease Primers, 7, 25.
<br>https://doi.org/10.1038/s41572-021-00259-0Cavallazzi, R., Furmanek, S., Arnold, F.W., et al. (2020) The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. Chest, 158, 1008-1016. <br>https://doi.org/10.1016/j.chest.2020.03.051Bein, T., Weber-Carstens, S. and Apfelbacher, C. (2018) Long-Term Outcome after the Acute Respiratory Distress Syndrome: Different from General Critical Illness? Current Opinion in Critical Care, 24, 35-40.
<br>https://doi.org/10.1097/MCC.0000000000000476Sangla, F., Legouis, D., Marti, P.E., et al. (2020) One Year after ICU Admission for Severe Community-Acquired Pneumonia of Bacterial, Viral or Unidentified Etiology. What Are the Outcomes? PLOS ONE, 15, e0243762.
<br>https://doi.org/10.1371/journal.pone.0243762Laporte, L., Hermetet, C., Jouan, Y., et al. (2018) Ten-Year Trends in Intensive Care Admissions for Respiratory Infections in the Elderly. Annals of Intensive Care, 8, 84. <br>https://doi.org/10.1186/s13613-018-0430-6World Health Organization (2021) Global Tuberculosis Report 2021. World Health Organization, Geneva.Walzl, G., Mcnerney, R., Du Plessis, N., et al. (2018) Tuberculosis: Advances and Challenges in Development of New Diagnostics and Biomarkers. The Lancet Infectious Diseases, 18, e199-e210.
<br>https://doi.org/10.1016/S1473-3099(18)30111-7World Health Organization (2018) Global Tuberculosis Re-port 2018. World Health Organization, Geneva.World Health Organization (2019) Global Tuberculosis Report 2019. World Health Organization, Geneva.World Health Organization (2020) Global Tuberculosis Report 2020. World Health Organization, Geneva.Zwerling, A., Van Den Hof, S., Scholten, J., et al. (2012) Interferon-Gamma Release Assays for Tuberculosis Screening of Healthcare Workers: A Systematic Review. Thorax, 67, 62-70. <br>https://doi.org/10.1136/thx.2010.143180Liang, H.Y., Li, X.L., Yu, X.S., et al. (2009) Facts and Fiction of the Relationship between Preexisting Tuberculosis and Lung Cancer Risk: A Systematic Review. International Journal of Cancer, 125, 2936-2944.
<br>https://doi.org/10.1002/ijc.24636Yu, Y.H., Liao, C.C., Hsu, W.H., et al. (2011) Increased Lung Cancer Risk among Patients with Pulmonary Tuberculosis: A Population Cohort Study. Journal of Thoracic Oncology: Official Pub-lication of the International Association for the Study of Lung Cancer, 6, 32-37. <br>https://doi.org/10.1097/JTO.0b013e3181fb4fccBrenner, D.R., Boffetta, P., Duell, E.J., et al. (2012) Previous Lung Diseases and Lung Cancer Risk: A Pooled Analysis from the International Lung Cancer Consortium. American Journal of Epidemiology, 176, 573-585.
<br>https://doi.org/10.1093/aje/kws151Leung, C.C., Hui, L., Lee, R.S., et al. (2013) Tuberculosis Is Associated with Increased Lung Cancer Mortality. The International Journal of Tuberculosis and Lung Disease: The Official Jour-nal of the International Union against Tuberculosis and Lung Disease, 17, 687-692. <br>https://doi.org/10.5588/ijtld.12.0816Getahun, H., Matteelli, A., Chaisson, R.E., et al. (2015) Latent Mycobac-terium tuberculosis Infection. The New England Journal of Medicine, 372, 2127-2135. <br>https://doi.org/10.1056/NEJMra1405427Rangaka, M.X., Cavalcante, S.C., Marais, B.J., et al. (2015) Con-trolling the Seedbeds of Tuberculosis: Diagnosis and Treatment of Tuberculosis Infection. The Lancet (London, England), 386, 2344-2353.
<br>https://doi.org/10.1016/S0140-6736(15)00323-2韩鹏勇, 塔娜, 等. 人CD8~+T细胞基因调控网络研究[J]. 西北农业学报, 2019, 28(6): 861-867.吴荷宁, 彭民. CD4~+T、CD8~+T淋巴细胞在新型冠状病毒肺炎中的研究进展[J]. 天津医科大学学报, 2021, 27(6): 658-660+664.安健, 孙蓬明. T淋巴细胞亚群检测在子宫内膜癌中的应用价值[J], 中国妇产科临床杂志, 2020, 21(4): 428-431.Westmeier, J., Paniskaki, K., Karaköse, Z., et al. (2020) Impaired Cytotoxic CD8(+) T Cell Response in Elderly COVID-19 Patients. mBio, 11, e02243-20. <br>https://doi.org/10.1128/mBio.02805-20Horkova, V., Drobek, A., Mueller, D., et al. (2020) Dynamics of the Coreceptor-LCK Interactions during T Cell Development Shape the Self-Reactivity of Peripheral CD4 and CD8 T Cells. Cell Reports, 30, 1504-1514.e7.
<br>https://doi.org/10.1016/j.celrep.2020.01.008Bardhan, K., Anagnostou, T. and Boussiotis, V.A. (2016) The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 7, 550. <br>https://doi.org/10.3389/fimmu.2016.00550Trefny, M.P., Kaiser, M., Stanczak, M.A., et al. (2020) PD-1(+) Natural Killer Cells in Human Non-Small Cell Lung Cancer Can Be Activated by PD-1/PD-L1 Blockade. Cancer Im-munology, Immunotherapy: CII, 69, 1505-1517.
<br>https://doi.org/10.1007/s00262-020-02558-zCooper, W.A., Tran, T., Vilain, R.E., et al. (2015) PD-L1 Ex-pression Is a Favorable Prognostic Factor in Early Stage Non-Small Cell Carcinoma. Lung Cancer (Amsterdam, Nether-lands), 89, 181-188.
<br>https://doi.org/10.1016/j.lungcan.2015.05.007Lindestam Arlehamn, C.S., Lewinsohn, D., Sette, A., et al. (2014) Antigens for CD4 and CD8 T Cells in Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 4, a018465. <br>https://doi.org/10.1101/cshperspect.a018465Kauffman, K.D., Sallin, M.A., Sakai, S., et al. (2018) Defective Positioning in Granulomas but Not Lung-Homing Limits CD4 T-Cell Interactions with Mycobacterium tuberculo-sis-Infected Macrophages in Rhesus Macaques. Mucosal Immunology, 11, 462-473. <br>https://doi.org/10.1038/mi.2017.60袁洁铭, 李理. 老年人T淋巴细胞PD-1高表达在炎症状态下对其功能的影响[J]. 免疫学杂志, 2017, 33(6): 519-524.Efremova, M., Rieder, D., Klepsch, V., et al. (2018) Targeting Immune Checkpoints Potentiates Immunoediting and Changes the Dynamics of Tumor Evolution. Nature Communica-tions, 9, Article No. 32.
<br>https://doi.org/10.1038/s41467-017-02424-0Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science (New York, NY), 359, 1350-1355. <br>https://doi.org/10.1126/science.aar4060Wykes, M.N. and Lewin, S.R. (2018) Immune Checkpoint Blockade in Infectious Diseases. Nature Reviews Immunology, 18, 91-104. <br>https://doi.org/10.1038/nri.2017.112Larbi, A., Franceschi, C., Mazzatti, D., et al. (2008) Aging of the Immune System as a Prognostic Factor for Human Longevity. Physiology (Bethesda, Md), 23, 64-74. <br>https://doi.org/10.1152/physiol.00040.2007Chinai, J.M., Janakiram, M., Chen, F., et al. (2015) New Immunotherapies Targeting the PD-1 Pathway. Trends in Pharmacological Sciences, 36, 587-595. <br>https://doi.org/10.1016/j.tips.2015.06.005Attanasio, J. and Wherry, E.J. (2016) Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity, 44, 1052-1068. <br>https://doi.org/10.1016/j.immuni.2016.04.022徐若楠, 孙国鹏, 等. PD-1基因的表达调控分子机制研究进展[J]. 中国免疫学杂志, 2020, 36(20): 2540-2546.Zhang, Y., Zhou, Y., Lou, J., et al. (2010) PD-L1 Blockade Improves Survival in Experimental Sepsis by Inhibiting Lymphocyte Apoptosis and Reversing Monocyte Dysfunction. Critical Care (London, England), 14, R220.
<br>https://doi.org/10.1186/cc9354Chang, K., Svabek, C., Vazquez-Guillamet, C., et al. (2014) Targeting the Pro-grammed Cell Death 1: Programmed Cell Death Ligand 1 Pathway Reverses T Cell Exhaustion in Patients with Sepsis. Critical Care (London, England), 18, R3. <br>https://doi.org/10.1186/cc13176Guignant, C., Lepape, A., Huang, X., et al. (2011) Programmed Death-1 Levels Correlate with Increased Mortality, Nosocomial Infection and Immune Dysfunctions in Septic Shock Patients. Critical Care (London, England), 15, R99.
<br>https://doi.org/10.1186/cc10112Bermejo-Martin, J.F. andaluz-Ojeda, D., Almansa, R., et al. (2016) Defining Immunological Dysfunction in Sepsis: A Requisite Tool for Precision Medicine. The Journal of Infection, 72, 525-536.
<br>https://doi.org/10.1016/j.jinf.2016.01.010Wherry, E.J. and Kurachi, M. (2015) Molecular and Cellular In-sights into T Cell Exhaustion. Nature Reviews Immunology, 15, 486-499. <br>https://doi.org/10.1038/nri3862Tezera, L.B., Bielecka, M.K., Ogongo, P., et al. (2020) Anti-PD-1 Immuno-therapy Leads to Tuberculosis Reactivation via Dysregulation of TNF-α. eLife, 9, e52668. <br>https://doi.org/10.7554/eLife.52668Day, C.L., Abrahams, D.A., Bunjun, R., et al. (2018) PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated with Bacterial Load in Human Tuberculosis. Fron-tiers in Immunology, 9, Article No. 1995.
<br>https://doi.org/10.3389/fimmu.2018.01995Hassan, S.S., Akram, M., King, E.C., et al. (2015) PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Pro-tein during the Intensive Phase of Tuberculosis Treatment. PLOS ONE, 10, e0137646. <br>https://doi.org/10.1371/journal.pone.0137646Basile, J.I., Liu, R., Mou, W., et al. (2020) Mycobacte-ria-Specific T Cells Are Generated in the Lung During Mucosal BCG Immunization or Infection with Mycobacterium tuberculosis. Frontiers in Immunology, 11, Article ID: 566319.
<br>https://doi.org/10.3389/fimmu.2020.566319Pathakumari, B., Devasundaram, S. and Raja, A. (2018) Altered Expression of Antigen-Specific Memory and Regulatory T-Cell Subsets Differentiate Latent and Active Tuberculosis. Immunology, 153, 325-336.
<br>https://doi.org/10.1111/imm.12833Singh, A., Mohan, A., Dey, A.B., et al. (2017) Programmed Death-1 (+) T Cells Inhibit Effector T Cells at the Pathological Site of Miliary Tuberculosis. Clinical and Experimental Immunology, 187, 269-283.
<br>https://doi.org/10.1111/cei.12871Singh, A., Dey, A.B., Mohan, A., et al. (2014) Programmed Death-1 Re-ceptor Suppresses γ-IFN Producing NKT Cells in Human Tuberculosis. Tuberculosis (Edinburgh, Scotland), 94, 197-206. <br>https://doi.org/10.1016/j.tube.2014.01.005Shen, L., Shi, H., Gao, Y., et al. (2016) The Characteris-tic Profiles of PD-1 and PD-L1 Expressions and Dynamic Changes during Treatment in Active Tuberculosis. Tuberculo-sis (Edinburgh, Scotland), 101, 146-150.
<br>https://doi.org/10.1016/j.tube.2016.10.001Singh, A., Mohan, A., Dey, A.B., et al. (2013) Inhibiting the Pro-grammed Death 1 Pathway Rescues Mycobacterium tuberculosis-Specific Interferon γ-Producing T Cells from Apopto-sis in Patients with Pulmonary Tuberculosis. The Journal of Infectious Diseases, 208, 603-615. <br>https://doi.org/10.1093/infdis/jit206Yin, W., Tong, Z.H., Cui, A., et al. (2014) PD-1/PD-Ls Pathways be-tween CD4 (+) T Cells and Pleural Mesothelial Cells in Human Tuberculous Pleurisy. Tuberculosis (Edinburgh, Scot-land), 94, 131-139.
<br>https://doi.org/10.1016/j.tube.2013.10.007